Cross-validation of a Shortened Battery for the Assessment of Dysexecutive Disorders in Alzheimer Disease. (April 2016)

• Record Type: Journal Article
• Authors: Godefroy, Olivier; Martinaud, Olivier; Verny, Marc; Mosca, Chrystèle; Lenoir, Hermine; Bretault, Eric; Devendeville, Agnès; Diouf, Momar; Pere, Jean-Jacques; Bakchine, Serge; Delabrousse-Mayoux, Jean-Philippe; Roussel, Martine
• Is Part Of: Alzheimer disease and associated disorders. Volume 30:Number 2(2016)
• Publication Date: 2016-04
• Subjects: Alzheimer disease -- mild cognitive impairment -- executive function -- attention -- apathy -- sensitivity and specificity; Alzheimer's disease -- Periodicals; Dementia -- Periodicals; 616.8305
• DOI: 10.1097/WAD.0000000000000112
• Languages: English
• ISSNs: 0893-0341

Abstract

Abstract : The frequency of executive disorders in mild-to-moderate Alzheimer disease (AD) has been demonstrated by the application of a comprehensive battery. The present study analyzed data from 2 recent multicenter studies based on the same executive battery. The objective was to derive a shortened battery by using the GREFEX population as a training dataset and by cross-validating the results in the REFLEX population. A total of 102 AD patients of the GREFEX study (MMSE=23.2±2.9) and 72 patients of the REFLEX study (MMSE=20.8±3.5) were included. Tests were selected and receiver operating characteristic curves were generated relative to the performance of 780 controls from the GREFEX study. Stepwise logistic regression identified 3 cognitive tests (Six Elements Task, categorical fluency and Trail Making Test B error) and behavioral disorders globally referred as global hypoactivity ( P =0.0001, all). This shortened battery was as accurate as the entire GREFEX battery in diagnosing dysexecutive disorders in both training group and the validation group. Bootstrap procedure confirmed the stability of AUC. A shortened battery based on 3 cognitive tests and 3 behavioral domains provides a high diagnosis accuracy of executive disorders in mild-to-moderate AD.